Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sygnis Pharma has received orphan drug designation from the European Commission for AX200 in the treatment of amyotrophic lateral sclerosis.
Subscribe to our email newsletter
The Sygnis research team has demonstrated in pre-clinical trials that AX200 counteracts the neuronal cell death and thereby decelerates the development of the disease. In the laboratory, protection of the motor neurons led to a reduced degeneration of muscles whilst maintaining muscular strength for a longer period of time.
Alfred Bach, CEO of Sygnis Pharma, said: “We are delighted to have obtained orphan drug status for AX200, our lead development compound, in amyotrophic lateral sclerosis. We intend to begin clinical trials within the next 12 months.”